Physician profile
Dan J Springer
NPI 1083664890
$4,472.55
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $797 · 2020: $776 · 2021: $1,034 · 2022: $1,033 · 2023: $768 · 2024: $65.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,021.53 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $602.44 | 2021-2023 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $449.10 | 2019-2023 | Wegovy |
| Amgen INC. | $416.01 | 2019-2023 | Evenity, Prolia |
| Pfizer INC. | $244.49 | 2019-2021 | |
| Astellas Pharma US INC | $235.57 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.83 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $124.23 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.06 | 2019-2022 | |
| Allergan, INC. | $92.85 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $92.84 | 2022-2024 | Spravato, Xarelto |
| Biohaven Pharmaceuticals, INC. | $90.00 | 2020-2021 | |
| Abbott Laboratories | $88.89 | 2020-2023 | Freestyle Libre 2 |
| Baxter Healthcare | $78.21 | 2022 | |
| Sunovion Pharmaceuticals INC. | $78.03 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.